Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 15 of 15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
NCT00183937
UroLift System With SAbR for Prostate Cancer and BPH
University of Texas Southwestern Medical Center
NCT05311527
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Andrei Iagaru
NCT03949517
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Viatar
NCT01943500
Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer
Massachusetts General Hospital
NCT00087347
A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02111187
Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
Rockefeller University
NCT00345293
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Pedro Barata, MD, MSc
NCT06312670
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
Dana-Farber Cancer Institute
NCT03070145
Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate Ca
William K. Oh
NCT01289067
Transpelvic Magnetic Stimulation to Improve Urogenital Function
VA Office of Research and Development
NCT04488068
Cisplatin in Castration Resistant Prostate Cancer
University of Rochester
NCT03275857
Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy
Barbara Ann Karmanos Cancer Institute
NCT00305747
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
Sensei Biotherapeutics
NCT03120832
Study of Focal Cryoablation in Low-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00774436
Ketogenic Diet and Prostate Cancer Surveillance Pilot
University of Maryland, Baltimore
NCT03194516
AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
Milton S. Hershey Medical Center
NCT05375539
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
Axogen Corporation
NCT00953277
Streaming Web-based Exercise At Home: A Pilot Study
Celina Shirazipour
NCT04282967
Transrectal Ultrasound (TRUS) in Finding Tumors During Robotic-Assisted Laparoscopic Surgery
University of Southern California
NCT01495130
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
NCT03418324
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Cancer Institute (NCI)
NCT03384316
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
NCT01205646
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma
NCT00818480
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine
University of Arkansas
NCT02485964
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients
University of California, San Francisco
NCT01008969
BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets
M.D. Anderson Cancer Center
NCT00872157
Fusion Targeted Biopsy of the Prostate
Emory University
NCT02013414
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Memorial Sloan Kettering Cancer Center
NCT02106507
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
Case Comprehensive Cancer Center
NCT02978586
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
NCT02064582
FACBC Prostate Therapy Response
Emory University
NCT02830880
Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer
Abramson Cancer Center at Penn Medicine
NCT02479945
Focal Prostate Radio-Frequency Ablation
H. Lee Moffitt Cancer Center and Research Institute
NCT02328807
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen
NCT03245736
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
GU Research Network
NCT02887976
To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.
US Department of Veterans Affairs
NCT00007579
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Barbara Ann Karmanos Cancer Institute
NCT00003626
Lycopene In Preventing of Prostate Cancer
University of Illinois at Chicago
NCT00006078
Calcifidol Therapy in Men With Cancer
US Department of Veterans Affairs
NCT00018538
CCI-779 in Treating Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT00012142
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00014352
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
NCT00045227
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
NCT00027859
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
Barr Laboratories
NCT00005623
Trastuzumab in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00003740
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Mayo Clinic
NCT00003038
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy
Memorial Sloan Kettering Cancer Center
NCT00006044
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer
American College of Radiology Imaging Network
NCT00032058
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.